LGALS3 and cervical carcinoma: Study conducted by Balasubramanian et al. [116] through using antigalectin-3 based ELISA and agglutination assays detected galectin-3 level of stages I–V of cervical cancer and found that stage dependent expression of galectin-3 approx. ranging from 1.0 to 3.3, 4.4 to 5.4, 5.4 to 24.7, 13.1 to 31.9, and 13.9 to 32.9 ng/mg C (creatinine) for stages I–V, respectively, indicating that galectin-3 is closely related to the stage of cervical cancer and galectin-3 may be used as a potential diagnostic tool for monitoring or follow-up of the stage of cancer disease.